Cytokinetics/$CYTK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cytokinetics
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Ticker
$CYTK
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
498
ISIN
US23282W6057
Website
Cytokinetics Metrics
BasicAdvanced
$4B
-
-$5.30
0.81
-
Price and volume
Market cap
$4B
Beta
0.81
52-week high
$61.38
52-week low
$29.31
Average daily volume
1.5M
Financial strength
Current ratio
5.986
Quick ratio
5.874
Long term debt to equity
-334.676
Total debt to equity
-351.28
Interest coverage (TTM)
-6.14%
Profitability
EBITDA (TTM)
-556.144
Gross margin (TTM)
-1,761.17%
Net profit margin (TTM)
-3,201.47%
Operating margin (TTM)
-2,943.30%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-34.12%
Return on equity (TTM)
185.72%
Valuation
Price to revenue (TTM)
200.365
Price to book
-14.84
Price to tangible book (TTM)
-14.84
Price to free cash flow (TTM)
-9.448
Free cash flow yield (TTM)
-10.58%
Free cash flow per share (TTM)
-350.98%
Growth
Revenue change (TTM)
412.21%
Earnings per share change (TTM)
-1.93%
3-year revenue growth (CAGR)
-33.39%
10-year revenue growth (CAGR)
-7.82%
3-year earnings per share growth (CAGR)
18.21%
10-year earnings per share growth (CAGR)
29.55%
What the Analysts think about Cytokinetics
Analyst ratings (Buy, Hold, Sell) for Cytokinetics stock.
Bulls say / Bears say
Cytokinetics has entered into a strategic funding collaboration with Royalty Pharma, providing up to $575 million to support the commercialization of aficamten and advance its cardiovascular pipeline. (benzinga.com)
Bayer has acquired rights to Cytokinetics' experimental heart drug in Japan, involving an upfront payment of €50 million and potential additional payments up to €580 million, indicating strong commercial interest. (reuters.com)
Analysts maintain a strong buy rating for Cytokinetics, with price targets ranging from $60 to $120, reflecting confidence in the company's growth prospects. (investing.com)
Goldman Sachs downgraded Cytokinetics' stock from 'Buy' to 'Neutral' and lowered the price target to $60, citing expectations of range-bound performance due to anticipated developments already being priced in. (investing.com)
Cytokinetics' CEO Robert Blum sold 16,970 shares worth $737,176, which could be perceived negatively by investors. (investing.com)
The company's CFO, Ching W. Jaw, announced his resignation effective February 23, 2025, to attend to a personal health condition, potentially raising concerns about leadership stability. (tradingview.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Cytokinetics Financial Performance
Revenues and expenses
Cytokinetics Earnings Performance
Company profitability
Cytokinetics News
AllArticlesVideos
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - CYTK
Accesswire·2 weeks ago
CYTK ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cytokinetics stock?
Cytokinetics (CYTK) has a market cap of $4B as of June 30, 2025.
What is the P/E ratio for Cytokinetics stock?
The price to earnings (P/E) ratio for Cytokinetics (CYTK) stock is 0 as of June 30, 2025.
Does Cytokinetics stock pay dividends?
No, Cytokinetics (CYTK) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Cytokinetics dividend payment date?
Cytokinetics (CYTK) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytokinetics?
Cytokinetics (CYTK) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.